Reevaluating safety pharmacology respiratory studies within the ICH S7A core battery: A multi-company evaluation of preclinical utility and clinical translation
Authors:
- 17 September 2024
- journal article
- research article
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 153, 105706
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Core battery safety pharmacology testing – An assessment of its utility in early drug developmentJournal of Pharmacological and Toxicological Methods, 2021
- Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse eventsJournal of Pharmacological and Toxicological Methods, 2019
- EEG: Characteristics of drug-induced seizures in rats, dogs and non-human primatesJournal of Pharmacological and Toxicological Methods, 2019
- Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational databaseToxicology and Applied Pharmacology, 2017
- Prediction of clinical risks by analysis of preclinical and clinical adverse eventsJournal of Biomedical Informatics, 2015
- Inclusion of Safety Pharmacology Endpoints in Repeat-Dose Toxicity Studies2015
- Safety pharmacology investigations in toxicology studies: An industry surveyJournal of Pharmacological and Toxicological Methods, 2013
- Cardiorespiratory safety evaluation in non-human primatesJournal of Pharmacological and Toxicological Methods, 2012
- Respiratory safety pharmacology: Positive control drug responses in Sprague–Dawley rats, Beagle dogs and cynomolgus monkeysRegulatory Toxicology and Pharmacology, 2009
- Benchmarking Safety Pharmacology regulatory packages and best practiceJournal of Pharmacological and Toxicological Methods, 2008